Axelia Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Axelia Pharmaceutical Export Portfolio Dataset — 2 Products, $1.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Axelia — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.6M Trade | TransData Nexus

Product Portfolio — Top 2 by Export Value

Axelia exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Caffeine	Respiratory & OTC	$1.5M	67	1.4%	11
2	Norfloxacin	Advanced Antibiotics	$151.1K	30	1.8%	14

Axelia exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.6M. The top category is Respiratory & OTC (90.8% of portfolio), followed by Advanced Antibiotics (9.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Axelia — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Axelia Laboratories, established on February 1, 2017, is a partnership firm headquartered in Palghar, Maharashtra, India. The company specializes in the manufacturing of pharmaceutical formulations, including tablets, capsules, syrups, and injections. Axelia's mission is to provide high-quality, affordable products that cure ailments, fortify the body, and enrich life.

The company's name, derived from the Ancient Greek divinity Axelia, symbolizes protection and nurturing, reflecting its commitment to safeguarding and enhancing human health. Axelia operates as a small enterprise, as classified in the financial year 2024-25. The firm's registered office is located at Plot No. 26, Pidco, Village Mahim, Palghar, Mumbai, Maharashtra, India. (axelialaboratories.linker.store)

2Manufacturing Facilities

Axelia Laboratories operates a manufacturing facility situated in Palghar, Maharashtra. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the facility is designed to meet the requirements of various pharmaceutical markets, ensuring the availability of quality products.

3Key Leadership

Axelia Laboratories is led by a team of directors who oversee the company's operations and strategic direction. The directors include Seemant Saurabh and Krushang Dinesh Boria, who have been associated with the company since November 2, 2020. The company's leadership is committed to upholding its mission of providing quality and affordable pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Axelia Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Axelia Laboratories has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has engaged in exporting pharmaceutical formulations to various countries, with notable shipments to regions such as Congo, Angola, and Sierra Leone. While specific regulatory filings and approvals in these markets are not publicly disclosed, Axelia's export activities indicate compliance with international standards and regulations.

2Emerging Markets

Axelia Laboratories has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's export data reveals shipments to countries such as Congo, Angola, and Sierra Leone. Additionally, Axelia has expressed interest in exporting to countries like Peru, indicating a strategic focus on diversifying its market presence. (axelialaboratories.linker.store)

3Geographic Strategy

Axelia Laboratories demonstrates a strategic approach to geographic diversification by exporting pharmaceutical formulations to various regions, including Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to countries such as Congo, Angola, and Sierra Leone. This diversification strategy helps mitigate concentration risk and positions Axelia to capitalize on growth opportunities in emerging markets.

Axelia — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Axelia Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export activities to various countries suggest adherence to international quality standards, but explicit FDA approvals and registrations are not disclosed.

2WHO & EU GMP

Axelia Laboratories' compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards is not publicly documented. While the company exports pharmaceutical formulations to various countries, specific certifications or prequalifications from WHO or EU GMP authorities are not available in the public domain.

3CDSCO & Indian Regulatory

Axelia Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facility in Palghar, Maharashtra, is authorized to produce pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed.

Axelia — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Axelia Laboratories operates in a competitive pharmaceutical export market, with numerous companies offering similar products across various therapeutic categories. While specific competitors are not identified in the available data, Axelia's focus on providing quality and affordable pharmaceutical formulations positions it to compete effectively in the global market.

2Key Differentiators

Axelia Laboratories differentiates itself through its commitment to quality and affordability in pharmaceutical formulations. The company's mission to protect life through good quality and affordable products reflects its dedication to customer well-being. Additionally, Axelia's strategic focus on exporting to diverse markets, including emerging economies, enhances its competitive edge.

3Strategic Position

Axelia Laboratories maintains a strategic focus on manufacturing and exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's export data indicates shipments to various countries, reflecting a commitment to expanding its global presence. While specific plans regarding generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services are not publicly disclosed, Axelia's emphasis on quality and affordability suggests a customer-centric approach to its strategic direction.

Buyer Due Diligence Brief — Evaluating Axelia as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Axelia Laboratories has demonstrated a consistent track record in exporting pharmaceutical formulations, with a total export value of $1.6 million USD across 97 shipments. The company's portfolio includes products such as caffeine and norfloxacin, indicating a focus on key therapeutic areas. The concentration of exports in two products across two therapeutic categories suggests a specialized approach to product offerings.

2Certifications to Verify

Importers considering Axelia Laboratories as a supplier should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm that Axelia's manufacturing facility is registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that Axelia's manufacturing practices comply with World Health Organization Good Manufacturing Practices. Verification can be obtained by reviewing the company's certifications or contacting the World Health Organization.

Frequently Asked Questions — Axelia

How many pharmaceutical products does Axelia export from India?

Axelia exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Caffeine ($1.5M), Norfloxacin ($151.1K). Total export value is $1.6M.

What is Axelia's total pharmaceutical export value?

Axelia's total pharmaceutical export value is $1.6M, based on 97 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Axelia cover?

Axelia exports across 2 therapeutic categories. The largest are Respiratory & OTC (90.8%, 1 products), Advanced Antibiotics (9.2%, 1 products).

Get Full Axelia Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Axelia

Axelia — Export Portfolio & Destination Treemap

Who is Axelia? — Company Overview & Market Position

What Does Axelia Export? — Product Portfolio Analysis

Top Products by Export Value

Axelia Therapeutic Categories — 2 Specializations